Bastiano Sanna - 01 Feb 2023 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Role
EVP, Cell & Genetic Therapies
Signature
/s/ Christiana Stevenson, Attorney-in-Fact
Issuer symbol
VRTX
Transactions as of
01 Feb 2023
Net transactions value
$0
Form type
4
Filing time
03 Feb 2023, 15:58:27 UTC
Previous filing
02 Feb 2023
Next filing
14 Feb 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRTX Common Stock Award $0 +9,092 +24% $0.000000 47,090 01 Feb 2023 Direct F1
transaction VRTX Common Stock Award $0 +12,314 +26% $0.000000 59,404 01 Feb 2023 Direct F2
transaction VRTX Common Stock Award $0 +7,866 +13% $0.000000 67,270 01 Feb 2023 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents earned performance shares with respect to a performance stock unit award granted on 03/01/2020 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/01/2023 and the shares will vest on 02/13/2023.
F2 Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2022 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/01/2023 and the shares will vest in installments beginning on 02/24/2023.
F3 Restricted stock unit award that vests in installments beginning on 02/10/2024.